THERAPY DOSSIER · th-ecf5715e37cd

1,8-cineole-loaded self-microemulsifying drug delivery system (CIN-SMEDDS)

Nutraceutical

Evidence & regulatory context

Mechanism: Not recorded
Target: Not recorded
Injury models: Endotoxin/LPS
Reported indication: Not recorded
First approval: Not recorded
Development stage: In trials, not approved
ChEMBL record: CHEMBL485259 ↗
ChEMBL max phase: 3 / 4 (development scale, not regulatory approval)
Synonyms: 1,8-cineole; 1,8-cineol; Cineole; Eucalyptol; Cajeputol; Terpan
Note: Not recorded

Clinical trials 1

0 linked trials carry an injury-indication flag. These flags support record-level exploration and sit alongside the stringent aggregate counts described in Methods.

NCT01119534 ↗PHASE3unknown

Comparative Efficacy of the Suppository Composed by Guaiacol, Eucalyptol, Menthol and Camphor Versus Guaiacol Suppository Versus Guaifenesin Syrup in Pediatric Patients With Cough

Cough

Enrolment: 270 · Results not recorded

Preclinical evidence 1

1 studies reported at therapy level; 1 evidence entries itemised.

PMID 30336203 ↗2018Reported benefit

Preparation and protective effects of 1,8-cineole-loaded self-microemulsifying drug delivery system on lipopolysaccharide-induced endothelial injury in mice.

MouseEndotoxin/LPSOral (used for the acute toxicity assay; median lethal dose 2998.9 mg/kg)

Model: Lipopolysaccharide-induced vascular endothelial injury in mice

CIN-SMEDDS inhibited IL-1beta, IL-6 and IL-8 with a simultaneous increase in IL-10 in lipopolysaccharide-treated mice and attenuated endothelial injury on histology, with effects associated with NF-kappaB and PPAR-gamma signalling.

Extraction: extract · Supplied extraction confidence: 0.6. Machine-extracted fields require source verification.

Loading the evidence…